WO2011117685A2 - Peptidos anticonceptivos derivados del veneno de la araña - Google Patents
Peptidos anticonceptivos derivados del veneno de la araña Download PDFInfo
- Publication number
- WO2011117685A2 WO2011117685A2 PCT/IB2010/054298 IB2010054298W WO2011117685A2 WO 2011117685 A2 WO2011117685 A2 WO 2011117685A2 IB 2010054298 W IB2010054298 W IB 2010054298W WO 2011117685 A2 WO2011117685 A2 WO 2011117685A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- contraceptive
- peptide
- seq
- sperm
- agent
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 64
- 239000003433 contraceptive agent Substances 0.000 title claims abstract description 26
- 230000002254 contraceptive effect Effects 0.000 title claims abstract description 26
- 102000004196 processed proteins & peptides Human genes 0.000 title description 18
- 239000002708 spider venom Substances 0.000 title description 3
- 238000000034 method Methods 0.000 claims abstract description 24
- 239000000934 spermatocidal agent Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 9
- 238000003786 synthesis reaction Methods 0.000 claims abstract description 9
- 244000005700 microbiome Species 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 229940124558 contraceptive agent Drugs 0.000 claims abstract description 5
- 239000002773 nucleotide Substances 0.000 claims abstract 5
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 5
- 238000010367 cloning Methods 0.000 claims abstract 3
- 239000003937 drug carrier Substances 0.000 claims abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- -1 flavorings Substances 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- 239000013598 vector Substances 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 239000003086 colorant Substances 0.000 claims description 2
- SOROIESOUPGGFO-UHFFFAOYSA-N diazolidinylurea Chemical compound OCNC(=O)N(CO)C1N(CO)C(=O)N(CO)C1=O SOROIESOUPGGFO-UHFFFAOYSA-N 0.000 claims description 2
- 229960001083 diazolidinylurea Drugs 0.000 claims description 2
- 229940061607 dibasic sodium phosphate Drugs 0.000 claims description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 2
- 239000003995 emulsifying agent Substances 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- 239000008020 pharmaceutical preservative Substances 0.000 claims description 2
- 239000004584 polyacrylic acid Substances 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 235000013772 propylene glycol Nutrition 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 abstract description 17
- 241001387432 Latrodectus mirabilis Species 0.000 abstract description 14
- 239000002435 venom Substances 0.000 abstract description 13
- 210000001048 venom Anatomy 0.000 abstract description 13
- 231100000611 venom Toxicity 0.000 abstract description 13
- 150000001413 amino acids Chemical class 0.000 abstract description 10
- 108020004511 Recombinant DNA Proteins 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 6
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 10
- 210000000287 oocyte Anatomy 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 231100000614 poison Toxicity 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000002574 poison Substances 0.000 description 7
- 230000001150 spermicidal effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108091006146 Channels Proteins 0.000 description 5
- 108090000862 Ion Channels Proteins 0.000 description 5
- 102000004310 Ion Channels Human genes 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 4
- LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 210000004907 gland Anatomy 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 229920004918 nonoxynol-9 Polymers 0.000 description 4
- 229940087419 nonoxynol-9 Drugs 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000019100 sperm motility Effects 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- FBWNMEQMRUMQSO-UHFFFAOYSA-N tergitol NP-9 Chemical compound CCCCCCCCCC1=CC=C(OCCOCCOCCOCCOCCOCCOCCOCCOCCO)C=C1 FBWNMEQMRUMQSO-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 210000000981 epithelium Anatomy 0.000 description 3
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000001012 protector Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- CBXCPBUEXACCNR-UHFFFAOYSA-N tetraethylammonium Chemical compound CC[N+](CC)(CC)CC CBXCPBUEXACCNR-UHFFFAOYSA-N 0.000 description 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 2
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 235000001258 Cinchona calisaya Nutrition 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- 241001313288 Labia Species 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000019802 Sexually transmitted disease Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 235000004279 alanine Nutrition 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000035558 fertility Effects 0.000 description 2
- 230000004720 fertilization Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- QBKSWRVVCFFDOT-UHFFFAOYSA-N gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 2
- 229950005277 gossypol Drugs 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000002515 oligonucleotide synthesis Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 125000001151 peptidyl group Chemical group 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229960000948 quinine Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- QFIIYGZAUXVPSZ-UHFFFAOYSA-N 8-(2,4-dihydroxy-6-methylanilino)-2-(2,4-dihydroxy-6-methylphenyl)imino-7-hydroxy-1,9-dimethyldibenzofuran-3-one Chemical compound CC1=CC(=CC(=C1NC2=C(C3=C(C=C2O)OC4=CC(=O)C(=NC5=C(C=C(C=C5C)O)O)C(=C43)C)C)O)O QFIIYGZAUXVPSZ-UHFFFAOYSA-N 0.000 description 1
- 102100031910 A-kinase anchor protein 3 Human genes 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 102100028062 Cation channel sperm-associated protein 2 Human genes 0.000 description 1
- 101710132770 Cation channel sperm-associated protein 2 Proteins 0.000 description 1
- 102100028061 Cation channel sperm-associated protein 3 Human genes 0.000 description 1
- 101710132768 Cation channel sperm-associated protein 3 Proteins 0.000 description 1
- 102100028014 Cation channel sperm-associated protein 4 Human genes 0.000 description 1
- 101710132763 Cation channel sperm-associated protein 4 Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 241000145313 Gymnocorymbus ternetzi Species 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- 101000945995 Latrodectus hasselti Alpha-latrotoxin-Lh1a Proteins 0.000 description 1
- 101000945994 Latrodectus hesperus Alpha-latrotoxin-Lhe1a Proteins 0.000 description 1
- 101000945997 Latrodectus mactans Alpha-latrotoxin-Lm1a Proteins 0.000 description 1
- 241000238868 Latrodectus tredecimguttatus Species 0.000 description 1
- 101000945996 Latrodectus tredecimguttatus Alpha-latrotoxin-Lt1a Proteins 0.000 description 1
- 241000699673 Mesocricetus auratus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 1
- 108010053775 Nisin Proteins 0.000 description 1
- 239000004218 Orcein Substances 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001380 anti-conceptive effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229940124462 contraceptive vaccine Drugs 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 229940124566 female contraceptive agent Drugs 0.000 description 1
- 108010042954 fibrous sheath protein 95 Proteins 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000003093 intracellular space Anatomy 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 108010070320 magainin A Proteins 0.000 description 1
- PIMDIROPKFPSDI-BXRJKVPUSA-N magainin-a Chemical compound C([C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)CCN)[C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(N)=O)C1=CC=CC=C1 PIMDIROPKFPSDI-BXRJKVPUSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000008384 membrane barrier Effects 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 229940045641 monobasic sodium phosphate Drugs 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000004309 nisin Substances 0.000 description 1
- 235000010297 nisin Nutrition 0.000 description 1
- 229920000847 nonoxynol Polymers 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000019248 orcein Nutrition 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000002135 phase contrast microscopy Methods 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 102000003998 progesterone receptors Human genes 0.000 description 1
- 108090000468 progesterone receptors Proteins 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940100611 topical cream Drugs 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 125000005500 uronium group Chemical group 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to peptides with contraceptive activity.
- the peptides are obtained from molecular fractions of the spider venom Latrodectus mirabilis.
- Contraception or contraception involves the use of different methods to prevent fertilization or pregnancy when having sex.
- spermicides are chemical compounds that kill or deactivate sperm.
- spermicides should affect sperm motility, affect the capacitive response, altering the membrane potential by blocking specific currents of some important ionic species to complete sperm maturation (such as Calcium), blocking progesterone receptors or substances that act as chemotactic components of the sperm.
- Nonoxynol-9 a bioorganic molecule that exerts its action primarily as a biodetergent of membrane structures. This means that it produces partial digestion of the membrane barrier constituent lipids. Thus, the biodetergent develops micropores in the membrane, destroying the barrier capacity that limits intra and extra cellular spaces, whereby transmembrane thermodynamic equilibrium and death of the affected cell are produced.
- Nonoxynol-9 are as an additive for barrier contraceptive methods (condom), used as a lubricant and spermicide; vaginal ovules containing 168 mg of substance; in contraceptive sponges that have 1,000 mg of substance; in lubricating gels for vaginal use and vaginal diaphragms.
- barrier contraceptive methods used as a lubricant and spermicide
- vaginal ovules containing 168 mg of substance in contraceptive sponges that have 1,000 mg of substance
- in lubricating gels for vaginal use and vaginal diaphragms in lubricating gels for vaginal use and vaginal diaphragms.
- FDA United States Food and Drug Administration
- Nonoxynol-9 in the presence of other cellular tissues (vaginal mucosa, cervical wall, lining membranes of the labia majora and labia in women and in man surface epithelium lining the glans area , lining epithelium of the urinary meatus) causes irritation, inflammation and keratosis.
- STDs Sexually Transmitted Diseases
- STDs sexually Transmitted Diseases
- lubricating gels have been designed for vaginal use. However, there are people who use them rectally, which given the presence of Nonoxynol-9 can promote disruption of the rectal epithelium.
- Spermicides can have natural or synthetic origin.
- An example of spermicide of natural origin is Gosipol. Since 1950 in China, Gosipol, which was obtained from cotton seeds, was extracted. This product appears as a potent contraceptive for men as it competitively inhibits lactic dehydrogenase that was important in sperm production. It was used in concentrations of 75 - 100 ⁇ g twice a month. The problem associated with this molecular structure was that it produced a chemical sterilization in individuals, so it could not be patented as a chemical spermicide, in addition to producing hypokalemia, effects at the level of the digestive system, fatigue and in extreme cases paralysis. The publication of Reddy et al.
- Antimicrobial peptides premises and promises" International Journal of Antimicrobial Agents 24 (2004) 536-547, describes the potential contraceptive use of antimicrobial peptides that alter flow of ions through the membranes in sperm. Mention magainin-A and nisin as examples of said peptides. However, there is no reference to synthetic peptides or analogues obtained from a fraction of the poison of Latrodectus mirabilis.
- Patent application EP448464A1 describes a method to determine if a sperm undergoes the acrosomal reaction, using C3, C3b or iC3 proteins, or their fragments. It is described that antibodies against the aforementioned proteins or fragments could be used as male or female contraceptive vaccines. Even when alternatives of peptide or protein origin are mentioned herein, the purpose is the generation of a contraceptive vaccine, which differs from the present invention related to a spermicide based on extracts of Latrodectus mirabilis venom or a synthetic peptide based on nucleotide sequences obtained from the same extract.
- US Patent US6897291 B1 describes ion channels that can be used to identify potential molecules that could serve as contraceptives, however, it does not describe new contraceptive or spermicidal molecules, but only provides a method to identify them.
- Australian patent AU772403B2 describes polypeptides based on FSP95, a protein that is located in the sperm tail and has a role in the Motility once the sperm has been trained.
- the use of said polypeptides for contraceptive purposes is mentioned, however, there is no information in said publication regarding their effectiveness, since no biological data is described.
- US patent applications US20040157292-A1, US20090104604-A1, US20060257868-A1, US20090249499-A1, describe different ion channels (CatSperl, CatSper2, CatSper3, CatSper4, respectively). Said channels are used for infertility diagnosis, and all documents mention the use of preparations containing inhibitors of said channels as a possible contraceptive. In particular, antibodies against said ion channels are mentioned, however, contraceptive peptides are not suggested or mentioned.
- US patent application US20070105188A1 describes methods to identify potential contraceptive molecules, but does not describe such molecules.
- FIGURE 1 Amino acid sequence of the native peptide (upper part) and of three synthetic analogs constructed from it. The third row, called Ac- [Ala43] -Atx41 -62-NH2, shows the sequence of the analog that shows spermicidal activity, which was used to perform sperm motility tests and whose sequence is also presented in SEQ ID NO 2.
- FIGURE 2 Immobilizing effect of total venom (Vt), fractions (F) and constructed analog, in selected human sperm (swim up), incubated by 45 minutes in HTF medium. (Log atx: concentration log (in mg / ml) of spermicidal agent tested). The IC50 for the analog would be equivalent to 39.81 ⁇ g / ml. The IC50 for total venom would be equivalent to 17.8 ⁇ g / ml.
- FIGURE 3 The graph shows the result of the number of human sperm (sp) that fuse in the pellucid area of a female gamete (hamster oocyte).
- an untrained sperm is an inert cellular gamete that must undergo biochemical and electrophysiological changes in the process of transforming the inert cell gamete into a functional cell, a process known as training.
- the present invention relates to molecular fractions obtained from the venom of the Latrodectus mirabilis spider (common name: black widow or red pony spider). These molecular fractions have allowed the development of a line of peptide synthesis products with biopharmaceutical action, which induce biochemical and electrophysiological changes that affect mature and ejaculated sperm by modifying their fertilizing capacitive potential (preventing sperm from becoming train) Therefore, said biopharmaceutical action corresponds to a contraceptive activity, where the fertility response of the human sperm is inhibited.
- the active substance of the contraceptive of the present invention induces biochemical modifications on the sperm, in relation to changes in intracellular pH, modification in levels of intracellular nitric oxide production, induction of changes in intracellular Ca 2+ concentration, modification of mitochondrial potential and of membrane potential, as well as modifications in the intracellular potassium and calcium ionic currents.
- the peptide spermicide which corresponds to a modification of the peptide found in a molecular fraction of the poison of Latrodectus mirabilis, is a compound of low molecular weight (2387 Da), of easy molecular synthesis and acting on membrane mechanisms, mobilizers of calcium and potassium that affect the energetic and motor property of sperm, inhibiting its fertilizing capacity.
- the active substance is a 20 amino acid peptide that has water-soluble properties and can be crystallized by lyophilization techniques.
- the conditions of use of the active substance are found in a preparation where a gel is used for topical use or linked to an oil to add it to preservatives.
- the active agent of the present invention affects the fertilizing potential without altering the integrity of the cell membrane.
- the active substance acts as a pharmacological agent that inhibits the capacitive response of mature ejaculated sperm and transforming it into a non-fertilizing gamete.
- the present invention is directed to an active agent with contraceptive properties.
- Said active agent corresponds to a molecular fraction of the Spider venom Latrodectus mirabilis.
- the active agent corresponds to a peptide with a sequence according to SEQ ID NO 1, or similar sequences in at least 85%, obtained by chemical synthesis or by recombinant DNA technology.
- the active agent with contraceptive property corresponds to a peptide of between 10 and 30 amino acids, preferably 20 amino acids.
- Said preferred embodiment is exemplified in the sequence SEQ ID NO 2, or similar sequences by at least 85%, obtained by chemical synthesis or by recombinant DNA technology.
- the native structure of the venom of Latrodectus mirabilis is of high molecular weight (7843 Da) SEQ ID NO 1, and has three cysteine bridges (as shown in FIGURE 1, native peptide upper part and analogously constructed lower part).
- This structure makes the native biotechnologically inefficient peptide for transformation into a drug, due to the problems of protein curl and the correct formation of the disulfide bonds. Due to the above, the fragment comprising the active principle was isolated, and in turn, the cysteine in position 43 was replaced by alanine and in this way the disulfide bridge was removed, so that a "linear" peptide is obtained.
- the analog built presents a quaternary and secondary secondary structure.
- the distribution of electrical charges on the surface of the molecule corresponding to the modified peptide (SEQ ID NO 2) is such that adhesion to cell membranes is very efficient, reaching maximum doses to affect 100% of sperm (FIGURE 2) .
- the cell membranes have ionic receptors or channels that are sensitive in their binding to drugs or drugs in which the main molecule has an electric charge (due to the depolarization induced by the opening of channels).
- spermicidal active agents is also considered, for the preparation of a composition used as a lubricant and spermicide in condoms, vaginal ovules, in contraceptive sponges, in gels lubricants for vaginal use and vaginal diaphragms, in gel in the form of vaginal or pressurized film and topical cream.
- composition comprising the active agent also comprises, among others, a gel component to be added to preservatives on the inner side of the latter, or an ovule-shaped sun gel to dissolve in the vaginal canal at 37 ° C.
- the pharmaceutical composition containing the peptides of the present invention may comprise one or more of the following pharmaceutically acceptable excipients or vehicles selected from: solvents, diluting agents, suspending agents, emulsifying agents, antioxidants, pharmaceutical preservatives, coloring agents, flavoring agents, vehicles, excipient oily bases such as: Water, Glycerin, Propylene Glycol, Hydroxyethylcellulose, Diazolidinyl Urea, Monobasic Sodium Phosphate, Triethanolamine, Carcomer, Polyacrylic Acid, Dibasic Sodium Phosphate, Propylparaben, Methylparaben, among others.
- EXAMPLE A Obtaining active substance with spermicidal activity from the poison of Latrodectus mirabilis
- the Latrodectus mirabilis glands containing its poisonous extract must be obtained, with a content of 2 to 4 ⁇ per gland.
- the animals are eliminated by a cold blow, using dry ice.
- Its chelyceres which are the carrier structures of the glands, are removed.
- the glands are aliquoted into 2.5 ml eppendorf tubes, with 200 ⁇ of distilled water, in a cold environment (- 4 ° C).
- Biological material obtained, it is stored in an airtight container, in a cold chamber (- 20 ⁇ ), to be sent later to the fractionation and freeze-drying process.
- a Waters preparative chromatography system (Delta Prep model 4000) was used, coupled to a UV-VIS detector (model 486), Pharmacia LKB-Frac-200 fraction collector, Servogor 120 recorder .
- the experimental conditions were:
- the peptides used in this work were synthesized manually by solid phase synthesis.
- the t-Boc and Fmoc strategies used MBAR, BAR and Rink resins as solid support.
- the links were made, with 2.5 excess Boc-aa and DIC / HOBt in DCM / DMF (1: 1; v / v) for 1 hour and monitored by the Kaiser test.
- Re-coupling when necessary, was performed using 2.5 excess Boc-aa and TBTU and / or BOP with excess DIEA (pH between 8.0-9.0) in DMSO / NMP (1: 4; v / v) for 1 hour.
- EXAMPLE B Determination of the spermicidal effect of native SEQ ID NO 1 peptide in human sperm.
- the spermicidal effect of the native peptide and the constructed analog was tested by evaluation of sperm motility in human sperm. For this, 15 mL of 0.1% HTF-BSA medium (0.02 g BSA in 20 mL HTF) and 3 mL of 1% HTF-BSA medium (0.04 g BSA in 4 mL were placed in a tube HTF) and stabilized in an oven at 37 Q C. The human semen sample was then left in an oven for 25 minutes to liquefy (it was worked with 2.6 mL of total semen). Once the sample was liquefied, it was divided into 3 conical 15 mL tubes with 2 mL of warm 0.1% HTF-BSA in each tube.
- the preparation was then incubated for 1 hour at 37 Q C with the tube tilted at 45 Q (swim up). Once this stage was completed, the sperm cloud was removed and the supernatants were combined and then centrifuged for 8 minutes at 1800 rpm, discarding the supernatant. Then, a sperm count was performed obtaining a value of 10 million sperm selected per mL (10 * 10 6 / mL). Different were applied concentrations of total venom and the different venom fractions obtained by chromatography, as well as the analog constructed to samples of sperm already selected and counted and incubated in HTF medium at 37 ⁇ C for 45 min.
- a drop of the sample was removed and placed on a slide tempered to 36-37 Q C and it was placed on a coverslip, also at the same temperature.
- the microscope was observed, always on the thermal stage, at 400 magnifications.
- a field was observed and the sperm that move in a rectilinear progressive manner were subjectively assessed, these being the ones that cross the observation field.
- Sperm that rotate in a circle or move in an oscillatory manner are considered to have abnormal movements.
- the percentage indicated is that of sperm without progressive rectilinear movement of the total sperm accepted, the minimum acceptable value being 50%, versus the logarithm of the concentration of spermicidal agent used (log ATX: total venom, constructed analog or chromatographic fractions of poison; F47, F48, F50).
- the peptides were synthesized by chemical synthesis type t-boc which consists in developing a temporary protector of the ⁇ - ⁇ -aminogroups or acyl.labil-tert-butyloxycarbonyla group and for side chains, benzyl group derived protectors are used (Bzl) which are resistant to weak acids (trifluoroacetic acid; TFA) and are removed by strong acids such as hydrogen fluoride (HF).
- t-boc chemical synthesis type t-boc which consists in developing a temporary protector of the ⁇ - ⁇ -aminogroups or acyl.labil-tert-butyloxycarbonyla group and for side chains, benzyl group derived protectors are used (Bzl) which are resistant to weak acids (trifluoroacetic acid; TFA) and are removed by strong acids such as hydrogen fluoride (HF).
- TFA trifluoroacetic acid
- HF hydrogen fluoride
- ⁇ - ⁇ -aminogroups In the t-boc strategy, the deprotection of ⁇ - ⁇ -aminogroups is performed with a gradient of 30% -50% TFA in dichloromethane (DCM) and neutralization is with 5% TEA (Tetraethylammonium) in DCM (dichloromethane) 10% of DIPEA (N, N trazodiisopropylethylamine) in DCM. Deprotection of the ⁇ - ⁇ -aminogroups was done with 50% TFA in DCM and neutralization with 10% TEA.
- DCM dichloromethane
- DIPEA N, N trazodiisopropylethylamine
- the solvent system used in the presence of DIC / HOBt was a 50% mixture of DCM in DMF (dimethylformamide), while 20% of DMSO in NMP (N-methyl-) was used for BOP / DIPEA or TBTU / DIPEA. pyrrolidone).
- the incorporated amino acid is acetylated. Acetylation means a reaction with 20% acetic anhydride in DMF plus 3 drops of Pyr for 20 min.
- the Kaiser test was used to monitor the coupling and deprotection of the corresponding amino acids.
- the protectors of each amino acid were removed with anhydrous HF treatment at a concentration of 10 ml / gr. of peptidyl resin, using 10% anisole, dimethyl sulfate and thioanisole. Vacuum reservoirs and teflon bottles are used. The reaction occurs at 0 ° C on constant stirring for two hours due to a large amount of arginine residues and the same is done for the TOS side shield that is partially resistant to HF removal. After the end of the reaction, the HF is removed under vacuum by being neutralized by a solution of 80 mg of sodium carbonate in 800 ml of deionized water. The peptide was washed in ether (g) whereby the resin precipitates and the crude peptide is extracted with a solution of 5% and 50% acetic acid in water.
- the peptides were then cycled to form disulfide bonds.
- the material used is a 3-mouth ball of 3 L. capacity.
- the crude peptide is dissolved in 400 ml of deionized water using a magnetic stirrer, an oxygen pump and a pH meter. The solution is aerated for 72 hrs in a cold chamber between ⁇ ' ⁇ ' ⁇ at constant pH 7.0. The effectiveness of the delation is followed by RP-HPLC evaluation. Finally the peptide was lyophilized, purified and characterized by HPLC.
- EXAMPLE D Production of spermaticidal peptide (Ac- [Ala43] -Atx41 -62-NH2) by recombinant DNA technology.
- the spermaticidal peptide Ac- [Ala43] -Atx41-62-NH2 (PM 2387.72 Da) has a known amino acid sequence (SEQ ID NO 2) that allows determining the DNA sequence encoding said peptide (SEQ ID NO 4) .
- the sequence is possible to manufacture by conventional methods of DNA oligonucleotide synthesis and to which the respective restriction sites of the plasmidial vector that will be used for subcloning are added.
- plasmid vectors pF25 A and F allow the peptide to be expressed in extracts of Sf21 insect cell line or in BL21 codon plus bacteria from PROMEGA Corp. USA.
- the peptide obtained can be purified by the conventional HPLC method that allows its isolation and the obtaining of the required quantities according to the demand of the product.
- the native peptide (PM 7843.70 Da) has a known amino acid sequence (SEQ ID NO 1) that allows determining the DNA sequence encoding said peptide (SEQ ID NO 3).
- the sequence is possible to manufacture by conventional methods of DNA oligonucleotide synthesis and to which the respective restriction sites of the plasmidial vector that will be used for subcloning are added.
- plasmid vectors pF25 A and F allow the peptide to be expressed in extracts of Sf21 insect cell line or in BL21 codon plus bacteria from PROMEGA Corp. USA.
- the peptide obtained can be purified by the conventional HPLC method that allows its isolation and the obtaining of the required quantities according to the demand of the product.
- EXAMPLE F Reduction of the fertilizing capacity of sperm in the presence of total venom of Latrodectus mirabilis and of a constructed analogue.
- the decrease in the fertilizing capacity of human sperm was tested by hamster oocyte penetration tests according to the protocol initially described by Yanagimachi e ⁇ a / (1976). Soon, golden hamster oocytes were collected and their pellucid area was removed, then incubated with previously trained human sperm in a concentration of 10 7 sperm / ml. The incubation was prolonged for 3-6 hrs. The oocytes were subsequently washed to remove sperm that did not penetrate and then fixed and stained with orcein. The oocytes were observed by phase contrast microscopy and were only considered as penetrated by sperm when they contained a head in fear or a male pronucleus inside their cytoplasm.
- EXAMPLE G Pharmaceutical composition for topical application of the spermicide of the invention.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Insects & Arthropods (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Reproductive Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES10848300.9T ES2529713T3 (es) | 2010-03-23 | 2010-09-23 | Péptidos anticonceptivos derivados de veneno de araña |
BR112012024138A BR112012024138B8 (pt) | 2010-03-23 | 2010-09-23 | peptídeo anticoncepcional derivado do veneno da aranha latrodectus mirabilis, sequência nucleotídica, métodos para a obtenção do peptídeo, composição farmacêutica e usos do peptídeo e da composição farmacêutica |
EP10848300.9A EP2551280B1 (en) | 2010-03-23 | 2010-09-23 | Contraceptive peptides derived from spider venom |
CN201080066642.1A CN103097402B (zh) | 2010-03-23 | 2010-09-23 | 源自蜘蛛毒素的避孕肽 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CL261-2010 | 2010-03-23 | ||
CL2010000261A CL2010000261A1 (es) | 2010-03-23 | 2010-03-23 | Peptidos derivados del veneno de latrodectus mirabilis, secuencias que lo codifican, procedimiento de produccion de dichos peptidos, composiciones farmaceuticas que los comprenden, y uso anticonceptivos de las mismas. |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011117685A2 true WO2011117685A2 (es) | 2011-09-29 |
WO2011117685A3 WO2011117685A3 (es) | 2012-01-05 |
Family
ID=44657132
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2010/054298 WO2011117685A2 (es) | 2010-03-23 | 2010-09-23 | Peptidos anticonceptivos derivados del veneno de la araña |
Country Status (7)
Country | Link |
---|---|
US (1) | US8980842B2 (es) |
EP (1) | EP2551280B1 (es) |
CN (1) | CN103097402B (es) |
BR (1) | BR112012024138B8 (es) |
CL (1) | CL2010000261A1 (es) |
ES (1) | ES2529713T3 (es) |
WO (1) | WO2011117685A2 (es) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0448464A1 (fr) | 1990-03-20 | 1991-09-25 | Societe De Recherche Et De Developpement En Activation Et Communication Cellulaire | Procédé pour la mise en évidence de la capacité d'un spermatozoide à subir la réaction acrosomale |
AU772403B2 (en) | 1999-02-01 | 2004-04-29 | University Of Virginia Patent Foundation | Methods and compositions for modulating fertility |
US20040157292A1 (en) | 2001-05-03 | 2004-08-12 | Children's Medical Center | Sperm-specific cation channel, CatSper1, and uses therefor |
US6897291B1 (en) | 1997-10-22 | 2005-05-24 | Icagen, Incorporated | pH sensitive potassium channel in spermatocytes |
US20060257868A1 (en) | 2002-08-07 | 2006-11-16 | Children's Medical Center Corporation | Tissue specific genes and gene clusters |
US20070105188A1 (en) | 2003-07-23 | 2007-05-10 | Travis Alexander J | Method of determining sperm capacitation |
US20090104604A1 (en) | 2001-10-22 | 2009-04-23 | Children's Medical Center Corporation | Sperm-specific cation channel, catsper2, and uses therefor |
US20090249499A1 (en) | 2002-08-07 | 2009-10-01 | Moran Magdalene M | Sperm-specific cation channel, catsper4, and uses therefor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CL2007003884A1 (es) * | 2007-12-31 | 2009-09-25 | Laboratorios Andromaco S A | Péptido derivado del veneno de la araña viuda negra, procedimiento para preparar dicho péptido, composición farmacéutica que lo comprende, y uso de dicha composición para la preparación de un medicamente útil para el tratamiento de la disfunción sexual. |
-
2010
- 2010-03-23 CL CL2010000261A patent/CL2010000261A1/es unknown
- 2010-09-23 EP EP10848300.9A patent/EP2551280B1/en not_active Not-in-force
- 2010-09-23 ES ES10848300.9T patent/ES2529713T3/es active Active
- 2010-09-23 CN CN201080066642.1A patent/CN103097402B/zh not_active Expired - Fee Related
- 2010-09-23 WO PCT/IB2010/054298 patent/WO2011117685A2/es active Application Filing
- 2010-09-23 BR BR112012024138A patent/BR112012024138B8/pt not_active IP Right Cessation
-
2011
- 2011-03-22 US US13/053,751 patent/US8980842B2/en not_active Expired - Fee Related
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0448464A1 (fr) | 1990-03-20 | 1991-09-25 | Societe De Recherche Et De Developpement En Activation Et Communication Cellulaire | Procédé pour la mise en évidence de la capacité d'un spermatozoide à subir la réaction acrosomale |
US6897291B1 (en) | 1997-10-22 | 2005-05-24 | Icagen, Incorporated | pH sensitive potassium channel in spermatocytes |
AU772403B2 (en) | 1999-02-01 | 2004-04-29 | University Of Virginia Patent Foundation | Methods and compositions for modulating fertility |
US20040157292A1 (en) | 2001-05-03 | 2004-08-12 | Children's Medical Center | Sperm-specific cation channel, CatSper1, and uses therefor |
US20090104604A1 (en) | 2001-10-22 | 2009-04-23 | Children's Medical Center Corporation | Sperm-specific cation channel, catsper2, and uses therefor |
US20060257868A1 (en) | 2002-08-07 | 2006-11-16 | Children's Medical Center Corporation | Tissue specific genes and gene clusters |
US20090249499A1 (en) | 2002-08-07 | 2009-10-01 | Moran Magdalene M | Sperm-specific cation channel, catsper4, and uses therefor |
US20070105188A1 (en) | 2003-07-23 | 2007-05-10 | Travis Alexander J | Method of determining sperm capacitation |
Non-Patent Citations (3)
Title |
---|
REDDY ET AL.: "Antimicrobial peptides: premises and promises", INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, vol. 24, 2004, pages 536 - 547 |
See also references of EP2551280A4 |
YEUNG: "Effects of the ion-channel blocker quinine on human sperm volume, kinematics and mucus penetration, and the involvement of potassium channels", MOLECULAR HUMAN REPRODUCTION, vol. 7, no. 9, 2001, pages 819 - 828 |
Also Published As
Publication number | Publication date |
---|---|
BR112012024138B1 (pt) | 2020-01-14 |
EP2551280A2 (en) | 2013-01-30 |
BR112012024138B8 (pt) | 2020-01-28 |
US20110237523A1 (en) | 2011-09-29 |
US8980842B2 (en) | 2015-03-17 |
EP2551280A4 (en) | 2013-09-18 |
EP2551280B1 (en) | 2014-11-05 |
ES2529713T3 (es) | 2015-02-24 |
CN103097402B (zh) | 2014-07-23 |
WO2011117685A3 (es) | 2012-01-05 |
CN103097402A (zh) | 2013-05-08 |
BR112012024138A2 (pt) | 2017-10-31 |
CL2010000261A1 (es) | 2010-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6995933B2 (ja) | インターロイキン23受容体の経口ペプチド阻害剤および炎症性腸疾患を処置するためのそれらの使用 | |
Jiang et al. | Evaluation of tandem Chlamydia trachomatis MOMP multi-epitopes vaccine in BALB/c mice model | |
JPH11505521A (ja) | グルカゴン様ペプチド−2、ならびにその治療への使用 | |
SI8011553A8 (sl) | Postopek za pripravo nonapeptidnih in dekapeptidnih derivatov hormonov za sproščanje luteinizirajočega hormona | |
ES2677895T3 (es) | Ciclótidos como agentes inmunosupresores | |
CN102146122A (zh) | 一种具有宫缩作用药物的生产工艺 | |
BR112020019938A2 (pt) | polipeptídeos antigênicos de vírus sincicial respiratório | |
WO2016112208A2 (en) | Topical applications of kv1.3 channel blocking peptides to treat skin inflammation | |
NO333157B1 (no) | Fosfolipidblaere, modifiserte antigen-presenterende celler, fremgangsmate for inkorporering av antigener inn i dendrittiske celler og farmasoytisk sammensetning. | |
JP2020532501A (ja) | 糸球体の足細胞傷害型腎臓病を予防又は治療する薬物の調製へのアクテオシドの使用 | |
Khan et al. | Immunisation with a plasmid DNA vaccine encoding gonadotrophin releasing hormone (GnRH-I) and T-helper epitopes in saline suppresses rodent fertility | |
Guha | Biophysical mechanism‐mediated time‐dependent effect on sperm of human and monkey vas implanted polyelectrolyte contraceptive | |
Ellerman et al. | Immunologic behavior of human cysteine-rich secretory protein 1 (hCRISP1) in primates: prospects for immunocontraception | |
KR100795839B1 (ko) | 세균의 편모 구성인자 플라젤린을 유효성분으로 함유하는점막 백신 보조제 | |
CN104136082B (zh) | 医学用途 | |
JPH11503142A (ja) | クラミジアワクチン | |
WO2006083516A2 (en) | Modified cyanovirin-n polypeptide | |
KR101293777B1 (ko) | 알러지성 질환의 치료 및 예방을 위한 펩타이드 | |
WO2011117685A2 (es) | Peptidos anticonceptivos derivados del veneno de la araña | |
ES2543198T3 (es) | Mutantes de FSH | |
ES2244708T3 (es) | Vacunas hipoalergenicas contra la alergia basadas en el alergeno phl p 7 de polen de cola de zorro. | |
ES2391237T3 (es) | Composiciones y métodos para tratar disfunción eréctil | |
CN102015757A (zh) | 修饰的Cpn10以及PRR信号 | |
CN114555624A (zh) | 抗炎剂 | |
KR101301417B1 (ko) | 알러지성 질환의 치료 및 예방을 위한 펩타이드 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 201080066642.1 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010848300 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012024138 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112012024138 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: ERR Ref document number: 112012024138 Country of ref document: BR |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01E Ref document number: 112012024138 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112012024138 Country of ref document: BR Kind code of ref document: A2 Effective date: 20120924 |